Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

RayzeBio

Biotech & Life Sciences · San Diego, United States · Founded 2020 · IPO 2023 Unicorn

Defeating cancer with radiopharmaceutical medicines

Valuation
$3.74B
Market cap · 2026
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

22 investors on RayzeBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Samsara BioCapital
Versant Ventures
venBio Partners
Series B+ 19 investors entered at this stage
Deerfield
Venrock
Sofinnova Investments
Alexandria Venture Investments
Redmile Group
Logos Capital
Laurion Capital Management
Soleus Capital
TCGX
Viking Global Investors
Perceptive Advisors
Venrock Healthcare Capital Partners
OrbiMed
Wellington Management
Vivo Capital
Cormorant Asset Management
Ally Bridge Group
LifeSci Venture Partners
Acuta Capital Partners

Global footprint

Where RayzeBio has talent and traffic

AI talent share
0.8% of workforce is AI talent
(2 of 249 staff)
Core AI10.4%
Other AI10.4%
Non-AI workforce24799.2%
Workforce by country
6 countries with
team presence
🇺🇸 United States98.2%
🇯🇵 Japan0.7%
🇩🇪 Germany0.6%
🇦🇷 Argentina0.6%
🇫🇷 France0.6%
Top 5 of 6 shown
Web traffic by country
6K monthly visits
across markets
🇺🇸 United States73.3%
🇮🇳 India26.7%
Top 2 markets shown

Patent intelligence

$380k patent portfolio · 13 active families

Estimated portfolio value
$380k
0.01% of market cap · 173.1× smaller than top peer Ascentage Pharma ($66M)
13 active patent families
Where RayzeBio innovates CarcinosisRadioactive drugPharmaceutical drugTargeting ligandsMetal Chelator

Where RayzeBio concentrates vs peers

Each axis is a top-10 topic across RayzeBio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about RayzeBio

An AI-synthesized read of the highest-engagement posts about RayzeBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See RayzeBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles